[Clinical and allergological evaluation of  Tavegil (HS-592), a new antihistaminic drug].
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003875:Drug Eruptions / Q000188:drug therapy*; D004485:Eczema / Q000188:drug therapy*; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009450:Neurodermatitis / Q000188:drug therapy; D011759:Pyrrolidines / Q000627:therapeutic use; D014581:Urticaria / Q000188:drug therapy*
D006634:Histamine H1 Antagonists; D011759:Pyrrolidines
Ocena kliniczno-allergologiczna Tavegilu (HS-592) nowego leku przeciwhistaminowego.